BlackRock Inc. acquired more than 7.5 million shares of Omnicell during the second quarter. This purchase establishes a 16.58% stake in the medication management company. The investment is valued at approximately $313 million.
The disclosure follows a recent earnings report where Omnicell surpassed analyst estimates.
Connor Clark & Lunn Investment Management Ltd. separately purchased over 157,000 shares during the second quarter. Institutional investors now collectively own a majority of the company's stock.